Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity

Toxicology in Vitro

Volumn 40, Issue , 2017, Pages 170-183

  Chang, Shih Yu ^a   Voellinger, Jenna L ^a   Van Ness, Kirk P ^a   Chapron, Brian ^a   Shaffer, Rachel M ^a   Neumann, Thomas ^b   White, Collin C ^a   Kavanagh, Terrance J ^a   Kelly, Edward J ^a   Eaton, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fluke Hall 304   (United States)

Author keywords

Hepatotoxicity; Human hepatocytes; In vitro models; Microphysiological systems; Preclinical toxicology; Liver on a chip

Indexed keywords

AFLATOXIN B1; ALBUMIN; CYTOCHROME P450 1A1; CYTOCHROME P450 3A4; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; CYTOCHROME P450 1A2; CYTOCHROME P450 3A; HEPATOCYTE NUCLEAR FACTOR 4;

ANIMAL CELL; ARTICLE; BILE CANALICULUS; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; LIVER CELL; LIVER FUNCTION; LIVER TOXICITY; MICROFLUIDICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; ADULT; ANIMAL; CELL CULTURE TECHNIQUE; CHILD; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; PRECLINICAL STUDY; PROCEDURES; TOXIC HEPATITIS; TOXICITY TESTING; YOUNG ADULT;

ADULT; AFLATOXIN B1; ANIMALS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; FEMALE; HEPATOCYTE NUCLEAR FACTOR 4; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; RATS; TOXICITY TESTS; YOUNG ADULT;

EID: 85010208948     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2017.01.007     Document Type: Article

References (52)

1. Andersen, M.E., et al. Developing microphysiological systems for use as regulatory tools–challenges and opportunities. ALTEX 31:3 (2014), 364–367.
2. Bale, S.S., et al. In vitro platforms for evaluating liver toxicity. Exp. Biol. Med. (Maywood) 239:9 (2014), 1180–1191.
3. Berger, D.R., et al. Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. Hepatology 61:4 (2015), 1370–1381.
4. Berthier, E., Young, E.W., Beebe, D., Engineers are from PDMS-land, biologists are from Polystyrenia. Lab Chip 12:7 (2012), 1224–1237.
5. Borlak, J., Chougule, A., Singh, P.K., How useful are clinical liver function tests in in vitro human hepatotoxicity assays?. Toxicol. in Vitro 28:5 (2014), 784–795.
6. Burke, M.D., et al. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48:5 (1994), 923–936.
7. Chang, S.Y., et al. Liver and kidney on chips: microphysiological models to understand transporter function. Clin. Pharmacol. Ther. 100:5 (2016), 464–478.
8. Choi, K., et al. Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin. Tissue Eng. Part C Methods 20:8 (2014), 641–651.
9. Chu, V., et al. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab. Dispos. 37:7 (2009), 1339–1354.
10. Diaz, D., et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99:3 (1990), 737–747.
11. Eaton, D.L., Gallagher, E.P., Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 34 (1994), 135–172.
12. Elsherbiny, M.E., Brocks, D.R., The effect of CYP1A induction on amiodarone disposition in the rat. J. Pharm. Sci. 99:1 (2010), 539–548.
13. Esch, E.W., Bahinski, A., Huh, D., Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14:4 (2015), 248–260.
14. Griffith, L.G., Wells, A., Stolz, D.B., Engineering liver. Hepatology 60:4 (2014), 1426–1434.
15. Gross-Steinmeyer, K., Eaton, D.L., Dietary modulation of the biotransformation and genotoxicity of aflatoxin B(1). Toxicology 299:2–3 (2012), 69–79.
16. Gross-Steinmeyer, K., et al. Influence of Matrigel-overlay on constitutive and inducible expression of nine genes encoding drug-metabolizing enzymes in primary human hepatocytes. Xenobiotica 35:5 (2005), 419–438.
17. Heinonen, J.T., et al. Assessment of regional cytochrome P450 activities in rat liver slices using resorufin substrates and fluorescence confocal laser cytometry. Environ. Health Perspect. 104:5 (1996), 536–543.
18. Hewitt, N.J., et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39:1 (2007), 159–234.
19. Huh, D., et al. Reconstituting organ-level lung functions on a chip. Science 328:5986 (2010), 1662–1668.
20. Huh, D., Hamilton, G.A., Ingber, D.E., From 3D cell culture to organs-on-chips. Trends Cell Biol. 21:12 (2011), 745–754.
21. Hutson, S.M., et al. Regulation of albumin synthesis by hormones and amino acids in primary cultures of rat hepatocytes. Am. J. Phys. 252:3 Pt 1 (1987), E291–E298.
22. Jeon, J.S., et al. Generation of 3D functional microvascular networks with human mesenchymal stem cells in microfluidic systems. Integr. Biol. 6:5 (2014), 555–563.
23. Kelly, E.J., et al. Innovations in preclinical biology: ex vivo engineering of a human kidney tissue microperfusion system. Stem Cell Res. Ther., 4(Suppl. 1), 2013, S17.
24. Kim, H.J., Ingber, D.E., Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr. Biol. 5:9 (2013), 1130–1140.
25. Kim, H.J., et al. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12:12 (2012), 2165–2174.
26. Kleinman, H.K., Philp, D., Hoffman, M.P., Role of the extracellular matrix in morphogenesis. Curr. Opin. Biotechnol. 14:5 (2003), 526–532.
27. Knudsen, T.B., et al. FutureTox II: in vitro data and in silico models for predictive toxicology. Toxicol. Sci. 143:2 (2015), 256–267.
28. Kolwankar, D., et al. Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab. Dispos. 33:4 (2005), 524–529.
29. Lehmann, J.M., et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:5 (1998), 1016–1023.
30. Levitt, D.G., Levitt, M.D., Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int. J. Gen. Med. 9 (2016), 229–255.
31. Lutolf, M.P., Hubbell, J.A., Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23:1 (2005), 47–55.
32. Ma, Q., Lu, A.Y., CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos. 35:7 (2007), 1009–1016.
33. Madan, A., et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 31:4 (2003), 421–431.
34. Meredith, C., et al. Studies on the induction of rat hepatic CYP1A, CYP2B, CYP3A and CYP4A subfamily form mRNAs in vivo and in vitro using precision-cut rat liver slices. Xenobiotica 33:5 (2003), 511–527.
35. Molina, D.K., DiMaio, V.J., Normal organ weights in men: part II-the brain, lungs, liver, spleen, and kidneys. Am. J. Forensic Med. Pathol. 33:4 (2012), 368–372.
36. Paine, M.F., et al. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60:1 (1996), 14–24.
37. Reif, R., et al. Bile canalicular dynamics in hepatocyte sandwich cultures. Arch. Toxicol., 2015.
38. Roth, M., Obaidat, A., Hagenbuch, B., OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol. 165:5 (2012), 1260–1287.
39. Shulman, M., Nahmias, Y., Long-term culture and coculture of primary rat and human hepatocytes. Methods Mol. Biol. 945 (2013), 287–302.
40. Sohlenius-Sternbeck, A.K., Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol. in Vitro 20:8 (2006), 1582–1586.
41. Sung, J.H., Shuler, M.L., A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 9:10 (2009), 1385–1394.
42. Sutherland, M.L., Fabre, K.M., Tagle, D.A., The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Res. Ther., 4(Suppl. 1), 2013, I1.
43. Trask, O.J. Jr., Moore, A., LeCluyse, E.L., A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. Assay Drug Dev. Technol. 12:1 (2014), 16–27.
44. Trietsch, S.J., et al. Microfluidic titer plate for stratified 3D cell culture. Lab Chip 13:18 (2013), 3548–3554.
45. van der Meer, A.D., et al. Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. Lab Chip 13:18 (2013), 3562–3568.
46. Vernetti, L.A., et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp. Biol. Med. (Maywood), 2015.
47. Wang, J.D., et al. Quantitative analysis of molecular absorption into PDMS microfluidic channels. Ann. Biomed. Eng. 40:9 (2012), 1862–1873.
48. Weber, E.J., et al. Development of a microphysiological model of human kidney proximal tubule function. Kidney Int. 90:3 (2016), 627–637.
49. Werk, A.N., Cascorbi, I., Functional gene variants of CYP3A4. Clin. Pharmacol. Ther. 96:3 (2014), 340–348.
50. Wikswo, J.P., The relevance and potential roles of microphysiological systems in biology and medicine. Exp. Biol. Med. (Maywood) 239:9 (2014), 1061–1072.
51. Wong, I., Ho, C.M., Surface molecular property modifications for poly(dimethylsiloxane) (PDMS) based microfluidic devices. Microfluid. Nanofluid. 7:3 (2009), 291–306.
52. You, J., et al. Impact of nanotopography, heparin hydrogel microstructures, and encapsulated fibroblasts on phenotype of primary hepatocytes. ACS Appl. Mater. Interfaces 7:23 (2015), 12299–12308.